Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.
马萨诸塞州剑桥，2024年11月22日（GLOBE NEWSWIRE）——领先的活体生物治疗公司Seres Therapeutics, Inc.（纳斯达克股票代码：MCRB）今天宣布，总裁兼首席执行官埃里克·沙夫将在美国东部时间2024年12月3日下午4点30分参加派珀·桑德勒第36届年度医疗保健会议的炉边谈话。
A live webcast of the chat will be accessible through the "Events and Presentations" tab on the "Investors and News" section of the Company's website at and will be available for replay following the event.
聊天的网络直播可通过公司网站 “投资者和新闻” 部分的 “活动和演讲” 选项卡观看，并将在活动结束后重播。
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome therapeutic, and which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit .
关于 Seres Therapeut
Seres Therapeutics, Inc.（纳斯达克股票代码：MCRB）是一家临床阶段的公司，致力于通过新的活生物疗法改善医疗弱势群体的患者预后。塞雷斯领导了VoWST的成功开发和批准，这是第一款经美国食品药品管理局批准的口服微生物组疗法，并于2024年9月出售给雀巢健康科学。该公司正在开发 SER-155，在一项针对接受异基因造血干细胞移植 (allo-HSCT) 的患者的临床研究中，该药物已证明血液感染和相关并发症显著减少（与安慰剂相比）。SER-155 和该公司的其他管道计划旨在针对多种与疾病相关的途径，由标准克隆细胞库通过培育制成，而不是使用用于 VoWST 的捐赠者来源的生产工艺制成。除了 allo-HSCT 外，该公司还打算在其他医疗脆弱患者群体中评估 SER-155 和其他培育的活体生物治疗候选药物，包括自体造血干细胞移植患者、中性粒细胞减少的癌症患者、CAR-T 接受者、慢性肝病患者、实体器官移植接受者以及重症监护室和长期急性护理机构的患者。欲了解更多信息，请访问。
Investor and Media Contacts:
IR@serestherapeutics.com
投资者和媒体联系人：
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
Carlo Tanzi，博士
肯德尔投资者关系
ctanzi@kendallir.com
This press release was published by a CLEAR Verified individual.
本新闻稿由一位经过CLEAR认证的个人发布。
Source: Seres Therapeutics, Inc.
来源：Seres Therapeutics, Inc.
